Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has received approval from the US Food and Drug Administration (FDA) to conduct separate Phase II clinical studies for its drug candidate SSGJ-608. The molecule is set to be evaluated as a treatment for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr axSpA).
SSGJ-608 is capable of selectively binding to human IL-17A, neutralizing its activity, effectively inhibiting the release of inflammatory factors, and thereby playing a role in curbing the biological activity of IL-17A. The drug has previously demonstrated success in a pivotal regulatory Phase III clinical study for moderate-to-severe plaque psoriasis, achieving primary efficacy endpoints (PASI 75 and sPGA 0/1), as well as all key secondary efficacy endpoints (PASI 90, PASI 100, and sPGA 0).- Flcube.com
